Both atomoxetine and methylphenidate worked, but methylphenidate edges ahead in older kids
STUDY: Gao Y et al, Journal of Child Psychology and Psychiatry 2026
STUDY TYPE: Randomized, open-label, active-comparator trial
FUNDING: Chinese government and academic sources
Background
ADHD often brings quick, intense mood swings that cause more family friction than inattention alone. Atomoxetine and methylphenidate both treat ADHD, but which eases this lability is unclear.
The Study
- 150 medication-naive children, ages 7 to 16, with ADHD and significant emotional lability.
- Randomized 1:1, open-label, to atomoxetine or methylphenidate for 8 to 10 weeks.
- Main outcome: emotional lability subscale of the Conners’ Parent Rating Scale.
Results
Both medications eased emotional lability substantially, with no significant difference between them (p=.137). Effect sizes were large for both, numerically larger for methylphenidate (d=-1.46) than atomoxetine (d=-0.93); response rates ran 74% versus 63%. The benefit held up after adjusting for ADHD symptom change, so it wasn’t just a byproduct of better attention.
Neither medication improved better coping strategies, suggesting the benefit is not learned.
A secondary analysis found a difference by age. After age 9, methylphenidate outperformed atomoxetine on emotional control, with no gap in younger children.
Side Effects
Decreased appetite was most common in both groups (40%). Atomoxetine caused more lethargy (17%); methylphenidate caused more insomnia (13%). No serious events occurred.
Limitations
There was no placebo arm, so time or expectation could explain some improvement. The age finding came from an exploratory analysis, so treat it like a non-randomized finding in need of confirmation.
Practice Implications
- Based on this trial, both medications are reasonable for ADHD with prominent emotional outbursts.
- Parent training or skills-based therapy are also effective, as are micronutrients (which now have confirmation from larger trials since our 2019 interview with Julia Rucklidge)
—Chris Aiken, MD
Director, Psych Partners
Editor in Chief, Carlat Psychiatry Report
